Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Immunophenotyping reveals longitudinal changes in circulating immune cells during radium-223 therapy in patients with metastatic castration-resistant prostate cancer

View ORCID ProfileJ.H.A. Creemers, View ORCID ProfileM.J. van der Doelen, View ORCID ProfileS. van Wilpe, R. Hermsen, T. Duiveman-de Boer, View ORCID ProfileD.M. Somford, M.J.R. Janssen, View ORCID ProfileJ.P.M. Sedelaar, View ORCID ProfileN. Mehra, View ORCID ProfileJ. Textor, View ORCID ProfileH. Westdorp
doi: https://doi.org/10.1101/2020.11.11.20229831
J.H.A. Creemers
1Department of Tumor Immunology, Radboudumc, Nijmegen, The Netherlands
2Oncode Institute, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for J.H.A. Creemers
M.J. van der Doelen
3Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands
4Department of Urology, Radboudumc, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for M.J. van der Doelen
S. van Wilpe
1Department of Tumor Immunology, Radboudumc, Nijmegen, The Netherlands
3Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for S. van Wilpe
R. Hermsen
5Department of Nuclear Medicine, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Duiveman-de Boer
1Department of Tumor Immunology, Radboudumc, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D.M. Somford
6Department of Urology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for D.M. Somford
M.J.R. Janssen
7Department of Radiology and Nuclear Medicine, Radboudumc, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J.P.M. Sedelaar
4Department of Urology, Radboudumc, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for J.P.M. Sedelaar
N. Mehra
1Department of Tumor Immunology, Radboudumc, Nijmegen, The Netherlands
3Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for N. Mehra
J. Textor
1Department of Tumor Immunology, Radboudumc, Nijmegen, The Netherlands
8Data Science group, Institute for Computing and Information Sciences, Radboud University, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for J. Textor
H. Westdorp
1Department of Tumor Immunology, Radboudumc, Nijmegen, The Netherlands
3Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for H. Westdorp
  • For correspondence: Harm.Westdorp@radboudumc.nl
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Purpose Radium-223 improves overall survival (OS) in men with bone metastatic castration-resistant prostate cancer (mCRPC). While the exact mechanism behind this survival benefit remains unclear, radium-induced immunological mechanisms might contribute to the OS advantage. We performed a comprehensive evaluation of the immunological changes in mCRPC patients by phenotyping the peripheral blood mononuclear cells (PBMCs) during radium-223 therapy.

Experimental Design In this prospective, single-arm, exploratory study, PBMCs of 30 mCRPC patients were collected before, during, and after treatment with radium-223. Lymphocyte and monocyte counts were analyzed to get insight into general immune cell trends. Next, we analyzed changes in T cell subsets, myeloid-derived suppressor cells (MDSCs), and immune checkpoint expression using linear regression models. Per subset, the 6-month change (% of baseline) was determined. Bootstrapped 95% confidence intervals were used to measure the degree of uncertainty of our findings.

Results We observed a substantial decrease in absolute lymphocyte counts (−0.12 * 10^9 cells/L per injection, 95% CI: -0.143 - -0.102). Simultaneously, an increase was observed in the proportion of T cells that expressed costimulatory (ICOS) or inhibitory (TIM-3, PD-L1, and PD-1) checkpoint molecules. Moreover, the fraction of two immunosuppressive subsets – the regulatory T cells and the monocytic MDSCs – increased throughout treatment. These findings were not more pronounced in patients with an ALP response during therapy.

Conclusion Immune cell subsets in patients with mCRPC changed during radium-223 therapy, which warrants further research into the possible immunological consequences of these changes.

Competing Interest Statement

M.J. van der Doelen received research grants form Bayer (to institution) during the conduct of the study, travel expenses from Bayer, research grants from Janssen Pharmaceuticals, and personal fees from Astellas outside the submitted work. R. Hermsen is member of the advisory board of Bayer and received personal fees and travel expenses from Bayer outside the submitted work. D.M. Somford is a member of the advisory boards of Janssen Pharmaceuticals, Astellas and Bayer and received research grants from Astellas outside the submitted work. N. Mehra is a member of the advisory boards of Bayer, Bristol Myers Squibb, Roche, Merck Sharp and Dome, Astellas and Janssen Pharmaceuticals, and reports personal fees from Bayer, research grants and personal fees from Janssen Pharmaceuticals, research grants and personal fees from Merck Sharp and Dohme, research grants and personal fees from Roche, research grants and personal fees from Astellas, research grants and personal fees from AstraZeneca, research grants and personal fees from Sanofi, research grants from Pfizer an research grants from Genzyme outside the submitted work. No potential conflicts of interest were disclosed by the other authors.

Funding Statement

This research was partly funded by Bayer The Netherlands. The funding organization had no role in the design and conduct of the study, collection, management, analysis, interpretation of the data, and preparation, review, or approval of the abstract or the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the institutional review boards of the Radboudumc (Nijmegen, The Netherlands) and Canisius-Wilhelmina hospital (Nijmegen, The Netherlands).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data and code is available on GitHub.

https://github.com/jeroencreemers/Immunophenotyping-radium223-mCRPC

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted November 12, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Immunophenotyping reveals longitudinal changes in circulating immune cells during radium-223 therapy in patients with metastatic castration-resistant prostate cancer
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Immunophenotyping reveals longitudinal changes in circulating immune cells during radium-223 therapy in patients with metastatic castration-resistant prostate cancer
J.H.A. Creemers, M.J. van der Doelen, S. van Wilpe, R. Hermsen, T. Duiveman-de Boer, D.M. Somford, M.J.R. Janssen, J.P.M. Sedelaar, N. Mehra, J. Textor, H. Westdorp
medRxiv 2020.11.11.20229831; doi: https://doi.org/10.1101/2020.11.11.20229831
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Immunophenotyping reveals longitudinal changes in circulating immune cells during radium-223 therapy in patients with metastatic castration-resistant prostate cancer
J.H.A. Creemers, M.J. van der Doelen, S. van Wilpe, R. Hermsen, T. Duiveman-de Boer, D.M. Somford, M.J.R. Janssen, J.P.M. Sedelaar, N. Mehra, J. Textor, H. Westdorp
medRxiv 2020.11.11.20229831; doi: https://doi.org/10.1101/2020.11.11.20229831

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Oncology
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1096)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (500)
  • Epidemiology (9767)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2308)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1559)
  • Health Policy (736)
  • Health Systems and Quality Improvement (603)
  • Hematology (236)
  • HIV/AIDS (503)
  • Infectious Diseases (except HIV/AIDS) (11641)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (237)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2142)
  • Nursing (134)
  • Nutrition (336)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (517)
  • Oncology (1176)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (146)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2180)
  • Public and Global Health (4657)
  • Radiology and Imaging (778)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (210)
  • Surgery (251)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)